DE60126614D1 - 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten - Google Patents

1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten

Info

Publication number
DE60126614D1
DE60126614D1 DE60126614T DE60126614T DE60126614D1 DE 60126614 D1 DE60126614 D1 DE 60126614D1 DE 60126614 T DE60126614 T DE 60126614T DE 60126614 T DE60126614 T DE 60126614T DE 60126614 D1 DE60126614 D1 DE 60126614D1
Authority
DE
Germany
Prior art keywords
diazepan
receptor antagonists
dione derivatives
dione
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60126614T
Other languages
English (en)
Other versions
DE60126614T2 (de
Inventor
Guido Galley
Annick Goergler
Thierry Godel
Reinhard Heck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60126614D1 publication Critical patent/DE60126614D1/de
Publication of DE60126614T2 publication Critical patent/DE60126614T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60126614T 2000-05-25 2001-05-18 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten Expired - Lifetime DE60126614T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00111249 2000-05-25
EP00111249 2000-05-25
PCT/EP2001/005723 WO2001090083A1 (en) 2000-05-25 2001-05-18 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists

Publications (2)

Publication Number Publication Date
DE60126614D1 true DE60126614D1 (de) 2007-03-29
DE60126614T2 DE60126614T2 (de) 2007-11-22

Family

ID=8168838

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60126614T Expired - Lifetime DE60126614T2 (de) 2000-05-25 2001-05-18 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten

Country Status (18)

Country Link
US (1) US6452001B2 (de)
EP (1) EP1296961B1 (de)
JP (1) JP4060596B2 (de)
KR (1) KR100526696B1 (de)
CN (1) CN1178923C (de)
AR (1) AR028607A1 (de)
AT (1) ATE353881T1 (de)
AU (2) AU2001281778B2 (de)
BR (1) BR0111062A (de)
CA (1) CA2409842C (de)
DE (1) DE60126614T2 (de)
DK (1) DK1296961T3 (de)
ES (1) ES2280392T3 (de)
MX (1) MXPA02011464A (de)
PE (1) PE20011266A1 (de)
PT (1) PT1296961E (de)
WO (1) WO2001090083A1 (de)
ZA (1) ZA200208940B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
WO2007074170A2 (de) * 2005-12-29 2007-07-05 Immupharma France Sa Compositions and methods for the treatment and prevention of disease
EP1973887B1 (de) * 2005-12-29 2012-09-19 Immupharma France SA Aza-heterocyclen zur behandlung von malaria oder aids
US20080033167A1 (en) 2005-12-29 2008-02-07 Gilles Guichard Compositions and methods for synthesizing heterocyclic therapeutic compounds
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
CN101405276A (zh) * 2005-12-29 2009-04-08 安姆弗拉玛法国股份公司 用于抑制磷脂酶a2的组合物和方法
BRPI0712557A2 (pt) * 2006-05-26 2013-07-02 Novartis Ag inibidores de aldosterona sintase e/ou 11 beta-hidrolase
US20100105688A1 (en) 2007-01-24 2010-04-29 Glaxo Group Limited Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
KR101044833B1 (ko) * 2010-02-10 2011-06-28 (주)혜성나노텍 무차광 온실 보온커텐 종형 개폐장치
JP5858917B2 (ja) * 2010-08-26 2016-02-10 興和株式会社 イソキノリン誘導体又はその塩の新規製造方法
AU2012274110A1 (en) 2011-06-24 2014-01-16 Construction Research & Technology Gmbh Cementitious composition and admixture
CN108358893A (zh) * 2018-02-10 2018-08-03 安徽唯诗杨信息科技有限公司 一种一锅法合成四氢化苯并-[1,4]-二氮杂环庚烷衍生物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022765A (en) 1975-01-06 1977-05-10 E. R. Squibb & Sons, Inc. Triazolo[4,3-d][1,4]benzodiazepine-6-ones
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SK283070B6 (sk) 1993-12-29 2003-02-04 Merck Sharp & Dohme Limited Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
PE20011266A1 (es) 2001-12-14
PT1296961E (pt) 2007-05-31
AU8177801A (en) 2001-12-03
ZA200208940B (en) 2004-02-04
KR100526696B1 (ko) 2005-11-08
CA2409842C (en) 2008-07-29
BR0111062A (pt) 2003-06-10
MXPA02011464A (es) 2003-04-25
KR20030003759A (ko) 2003-01-10
US20020010174A1 (en) 2002-01-24
ATE353881T1 (de) 2007-03-15
JP4060596B2 (ja) 2008-03-12
US6452001B2 (en) 2002-09-17
CN1178923C (zh) 2004-12-08
WO2001090083A1 (en) 2001-11-29
CN1430611A (zh) 2003-07-16
JP2003534332A (ja) 2003-11-18
ES2280392T3 (es) 2007-09-16
EP1296961A1 (de) 2003-04-02
AR028607A1 (es) 2003-05-14
DK1296961T3 (da) 2007-06-04
CA2409842A1 (en) 2001-11-29
EP1296961B1 (de) 2007-02-14
AU2001281778B2 (en) 2005-06-02
DE60126614T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
ATE261945T1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE250039T1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60014216D1 (de) 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
ATE280158T1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60112607D1 (de) 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60135239D1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60001840D1 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
DE60129841D1 (de) Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
NO20043064L (no) 1-alkyl-1-azoniabisyklo [2.2.2] oktankarbamatderivater og anvendelse av disse som muskarine reseptorantagonister
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60336266D1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten
ATE293620T1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
ATE353881T1 (de) 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
ATE283844T1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
DE60123458D1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
ATE401333T1 (de) 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
ATE329908T1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
ATE353325T1 (de) 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition